This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Halcox, J. P.J. Articles by Deanfield, J. E. Search for Related Content PubMed PubMed Citation Articles by Halcox, J. P.J. Articles by Deanfield, J. E.

(Circulation. 2004;109:II-42 – II-48.)
© 2004 American Heart Association, Inc.

Vascular Effects of Statins

Beyond the Laboratory

Clinical Implications for Statin Pleiotropy

Julian P.J. Halcox, MB, MA, MRCP; John E. Deanfield, MB, FRCP

From the Vascular Physiology Unit, Department of Cardiology, Institute of Child Health, University College London, London, England.

Correspondence to John E. Deanfield, MB, FRCP, Vascular Physiology Unit, Institute of Child Health, 30 Guildford St, London WC1N 1EH, England. E-mail DEANFJ{at}gosh.nhs.uk

Abstract

Results from large-scale clinical trials of lipid lowering with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have led to a revolution in the management of atherosclerosis. In addition to their potent effect on serum lipid levels, statins influence several other cellular pathways, including those involving inflammatory, oxidative, and thrombotic processes. These effects clearly have the potential to beneficially modify the atherogenic process, and it has been suggested that they contribute to the impressive results seen in the clinical trials. We review the clinical evidence for benefits of statin therapy that are distinct from their effect on lipid biology. In particular, we address three key issues: the role of statins in diseases not traditionally associated with elevated cholesterol levels; whether clinical benefits are seen with statin therapy before an effect on lipid levels; and whether the magnitude of clinical benefit observed with statin therapy is unrelated to the degree of cholesterol reduction. At present, low-density–lipoprotein lowering seems to be the primary mechanism underlying the clinical benefits of statin therapy and should remain the focus of risk-reduction strategies in clinical practice.

Key Words: lipids • atherosclerosis • inflammation • prevention